Niizuma Hidetaka, Cheng Emily H, Hsieh James J
Human Oncology & Pathogenesis Program; Memorial Sloan-Kettering Cancer Center; New York, NY, USA; Department of Pediatrics; Tohoku University Graduate School of Medicine; Sendai, Miyagi, Japan.
Human Oncology & Pathogenesis Program; Memorial Sloan-Kettering Cancer Center; New York, NY, USA; Department of Pathology; Memorial Sloan-Kettering Cancer Center; New York, NY, USA.
Mol Cell Oncol. 2015 Jan 23;2(4):e999513. doi: 10.1080/23723556.2014.999513. eCollection 2015 Oct-Dec.
Taspase 1 (TASP1) cleaves the mixed-lineage leukemia (MLL) and transcription factor (TF) IIA families of nuclear proteins to orchestrate various biological processes. TASP1 is not a classical oncogene, but assists in cell proliferation and permits oncogenic initiation through cleavage of MLL and TFIIA. TASP1 is thus better classified as a "non-oncogene addiction" protease, and targeting TASP1 offers a novel and attractive anticancer therapeutic strategy.
塔斯帕酶1（TASP1）可切割核蛋白的混合谱系白血病（MLL）和转录因子（TF）IIA家族，以协调各种生物学过程。TASP1不是经典的癌基因，但通过切割MLL和TFIIA来协助细胞增殖并促进致癌起始。因此，TASP1更适合归类为“非癌基因成瘾”蛋白酶，靶向TASP1提供了一种新颖且有吸引力的抗癌治疗策略。
